Evaluation of nephrotoxicity and prognosis in patients treated with colistin due to hospital-acquired pneumonia
INTroducTIoN
Nosocomial infections that develop due to multidrugresistant (MDR) gram-negative bacteria lead to increased morbidity and mortality (1). The increase in the incidence of such infections and the lack of development of new antibiotics have led to reconsideration of colistin as a treatment option. Colistin belongs to the polymyxin group of antibiotics, the use of which was gradually abandoned after 1970's because of its side effects such as nephrotoxicity and neurotoxicity (2) . It is currently used via intravenous and inhalation routes in the treatment of infections due to MDR Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae (3, 4) . The use of colistimethate sodium (CMS) in Turkey has a similar history. An imported brand was used until September 2010. A domestically produced brand was licensed in April 2010 and marketed thereafter.
The safety and efficacy of polymyxins in the treatment of nosocomial infections caused by MDR gram-negative bacteria have been investigated in several studies (5, 6) . Despite their efficacy, serious side effects such as nephrotoxicity, neurotoxicity, and skin toxicity led to concerns regarding their use (7) . The nephrotoxicity has been reported to range widely between 0-53.5% (8) .
There are limited reports from Turkey reflecting the clinical experience with CMS. These studies were included few patients with hospital-acquired pneumonia (HAP) (9, 10) . The primary objectives of this study were to evaluate the frequency of nephrotoxicity and the parameters affecting nephrotoxicity in patients treated with CMS for HAP due to MDR P. aeruginosa or A. baumannii. The secondary objective was to determine the prognosis in this population.
MATErIALs and METHods
Patients hospitalized at seven tertiary care centers between February 2007 and November 2013 were included in this retrospective cohort study. Study period was identified according to domestic drug license time to assess equal time for different two drug brands. The study was approved by the ethics committee of the coordinating center; i.e. Ege University and was conducted in accordance with the ethical principles stated in the Declaration of Helsinki.
The cases hospitalized and treated with CMS within the given time period were screened and selected from databases of each hospital. Study inclusion criteria: 1) Patients treated with parenteral CMS for HAP associated with MDR P. aeruginosa or A. baumannii. Study exclusion criteria: 1) CMS administration for less than three days, 2) Administration of inhaled CMS alone, 3) No documentation of Pseudomonas or Acinetobacter infection, 4) Presence of chronic renal failure, 5) No regular follow-up of renal function tests.
Demographic characteristics, diagnosis at time of admission, underlying conditions, APACHE (Acute Physiology Assessment and Chronic Health Evaluation) II score at the time of diagnosis, presence and severity of hypoxemia and its treatment, and renal functions were recorded (11) . In patients who had received CMS for more than one episode, only the data from the first treatment episode was taken into consideration.
diagnosis of HAP
HAP was clinically diagnosed in patients who had new or progressive pulmonary infiltrates on chest radiographs obtained at least 48 hours post-admission and who was reported two or more of the following symptoms: Fever (> 38°C) or hypothermia (< 36°C); leukocytosis (> 10.000/mm 3 ) or leukopenia (< 4000/ mm 3 ); presence of purulent tracheal secretions (12, 13) .
A clinical diagnosis of ventilator-associated pneumonia (VAP) was made if they met the above-mentioned criteria and they had been receiving invasive mechanical ventilation for more than 48 hours (12, 13) .
Microbiological Evaluation
Sputum, endotracheal aspirate, non-bronchoscopic bronchoalveolar lavage (mini-BAL) or bronchoscopic materials (bronchoscopic aspirates, BAL) were used as respiratory specimens for bacteriologic cultures. Blood cultures were performed in patients with fever or hypothermia; pleural fluid cultures were done when pleural fluid was present.
The threshold values for the quantitative evaluation of lower respiratory tract samples other than sputum were 10 5 cfu/mL for endotracheal aspirates drawn via a protected sterile catheter and 10 4 cfu/mL for mini-BAL and BAL. VITEK 2 automated system (bioMérieux SA, Marcy-l'Etoile, France) and conventional methods were used according to "Clinical and Laboratory Standards Institute (CLSI)" criteria to identify the causative bacteria and their antibiotic susceptibilities (14) .
Detection of intermediate susceptibility or resistance to at least three antibiotic groups was accepted as "MDR" (15) .
cMs Treatment
The patients were treated with an imported brand of CMS In the result section, patients were evaluated in two groups as "high dose/kg" for domestic brand and "low dose/kg" for imported brand according to used colistin dose depending on brand.
Presence of CMS combination with other antibiotics for the treatment of the same HAP episode was also recorded.
Nephrotoxicity Evaluation
Nephrotoxicity was assessed according to the RIFLE criteria (17) . In order to determine the "baseline creatinine" level of the patients, their serum creatinine levels were examined from the time of admission to the first day of CMS treatment. These levels were compared to the estimated creatinine level based on age and gender; the lower level was accepted as the patient's baseline creatinine level (18) . The serum creatinine levels at the time of admission, initiation of CMS therapy and during hospitalisation were recorded. The patient's RIFLE stage was calculated using the baseline creatinine level and the levels measured at these time periods (17) . Nephrotoxicity was defined as a worsening in the RIFLE stage with respect to the RIFLE stage at the first day of CMS treatment or need for dialysis after the initiation of CMS treatment. In cases who developed nephrotoxicity, changes in the antibiotic dosing and in treatment regimens, use of renal replacement therapy were recorded. The recovery of renal function in response to therapy was categorized as "complete" (improvement in the serum creatinine level, the final creatinine level < 1.5 x baseline level), "partial" (improvement in the serum creatinine level, the final creatinine level ≥ 1.5 x baseline level), or "unresponsive" (no renal function recovery or initiation of renal replacement therapy) based on the latest serum creatinine level of the patients who died and the creatinine levels through the follow-up period of the other patients (19) .
Presence of acute renal failure (ARF) before CMS therapy was recorded. This was defined as an abrupt (within 48 hours) reduction in kidney function based on an elevation in serum creatinine level, a reduction in urine output, the need for renal replacement therapy (dialysis), or a combination of these factors. During colistin treatment, the following parameters were recorded as other factors that could potentially have an impact on nephrotoxicity: dehydration, gastrointestinal bleeding, history of cardiopulmonary resuscitation (CPR), administration of diuretics, nonsteroidal anti-inflammatory drugs, contrast agents and other nephrotoxic drugs, presence of septic shock at the time HAP developed (20) .
Beside the patients' clinical response, bacterial eradication, durations of stay at the hospital and intensive care unit (ICU) and overall mortality at the hospital were evaluated. The clinical response was defined as the presence of at least one of the following criteria following 72 hours of antibiotic treatment: normalization of body temperature, decrease in respiratory secretions (and in the need for suctioning), decrease in the serum CRP level by at least 50%, decrease in the need for inotropic support, significant improvement in oxygenation. Bacteriological response was defined as no growth of the causative pathogen in cultures of lower respiratory specimens obtained at least 72 hours of antibiotic treatment. Additional infections acquired at the hospital that could affect the duration of stay at the hospital and mortality status were recorded.
statistical Analysis
The data management and analysis were done using SPPS 
cMs Treatment
Until 2010, the imported brand of CMS was used at a relatively lower dose, as recommended by the manufacturer, in the treatment of 58 cases. Thereafter, the domestic brand of CMS was used in the remaining 223 cases at a higher dose, again, as recommended by the manufacturer. Thus, the median CBA of the "low dose/kg" and "high dose/kg" groups for the first day of treatment were 180 (60-180) mg and 300 (75-450) mg, respectively (p< 0.001). In addition to the parenteral route, CMS was administered via inhalation in 69 of the cases and there was no difference between two groups [19 patients (32.8%) and 50 patients (22.4%), who used the imported and domestic parenteral brands, respectively (p= 0.12)].
CMS was combined with other antibiotics in 82.9% of the patients. Combination treatment was used at similar rates in the patients groups treated with the different dose because of CMS brands. The other antibiotics used in combination are shown in Table 2 .
response to Treatment
A clinical response and bacterial eradication were achieved in 52.0% and 61.0% (128 of 210 patients) of the cases, respectively. Control bacteriologic examination could be performed in 74.7% of the patients; thus, the eradication rate reflects the outcome in patients whose data were available. There was no significant difference in clinical response and bacterial eradication rates between monotherapy and combination therapy groups (p= 0.52 and p= 1.0, respectively). The median durations of ICU and hospital stay for all patients were found as 27.5 (0-132) and 34 (9-164) days, respectively. Invasive mechanical ventilation was applied to 247 cases due to respiratory failure.
There was no difference in clinical outcomes in the patients groups classified according to used dose depending on CMS brands (Table 3) . 
Nephrotoxicity
Nephrotoxicity developed at a mean of 8.4 ± 5.0 days after the initiation of CMS treatment in 62.3% of the patients; of these, 30.9% were in "injury" and 49.7% were in "failure" stage, as defined by RIFLE criteria. The risk factors that were likely to affect the development of nephrotoxicity are presented in Table  4 . The patients developing nephrotoxicity had lower RIFLE stages at the time of initiation of CMS therapy than the patients without nephrotoxicity (p= 0.023). In univariate analysis, nephrotoxicity was associated with advanced age (p= 0.004), increased weight (p= 0.017); presence of diabetes mellitus (p= 0.025) and of HAP-related sepsis (p= 0.023), red blood cells transfusion (p= 0.017), the use of high dose colistin measured as colistin base activity (p< 0.001) and the use of the domestic CMS brand (p< 0.001). Renal function worsened in 67.7% and 41.4% of patients who used the high and low dose CMS, respectively (p< 0.001).
The risk factors for nephrotoxicity in patients treated with high and low doses of colistin were separately examined (Table 5) . Multivariate logistic regression analysis showed that the development of nephrotoxicity was independently associated with used brand. Besides, all of the 23 patients required to dialysis because of nephrotoxicity were treated with high dose/kg CMS. The other independent variables associated with nephrotoxicity were increased age, male gender, hypertension, red blood cells transfusion, absence of acute kidney injury and the risk group of RIFLE stage (Table 6) .
Nephrotoxicity developed at similar rates in patients with HAP (63.2%) and VAP (61.7%).
Management of Nephrotoxicity
Among the 175 patients that developed nephrotoxicity; the CMS dose was decreased in 88 and CMS therapy was discontinued in 40. For renal recovery treatment, twenty-three patients needed to dialysis, and 86 cases received hydration or diuretic treatment depending on their fluid condition. As a result of these interventions; 23.2% of the cases fully recovered, 20.0% had partial recovery, whereas renal function did not recover in 45.7%. No information could be retrieved regarding the outcome of the remaining patients (11.1%).
Effect of Nephrotoxicity on clinical outcomes
When patients were compared in terms of developing nephrotoxicity during follow up for their clinical prognosis, the mortality rate was found to be higher in the group having nephrotoxicity (p= 0.022). There was no difference between two groups for other outcomes ( Table 7) .
Mortality and risk Factors
The overall mortality rate was found as 61.6%. Multivariate logistic regression analysis showed that the mortality was associated with advanced age [OR= APACHE II score at hospitalisation, the CMS brand, the CBA dose on first day of treatment, CMS-related nephrotoxicity, bacteriologic response to treatment, presence of sepsis, additional infection, bacteremia due to HAP, serum albumin level at hospitalisation, HAP or VAP diagnosis were not related to mortality.
dIscussIoN
This study showed that CMS therapy was associated with relatively high clinical and bacteriologic response rates in patients with HAP due to MDR P. aeruginosa or A. baumannii, but that it also led to the development of nephrotoxicity in a significant percentage of the patients. Importantly, the use of high dose/kg CMS depending on the brand was found to be one of the risk factors for nephrotoxicity. Besides, advanced age, male gender, presence of hypertension, red blood cells transfusion and low RIFLE stages were other risk factors. Although the mortality was found to be higher in the patients who developed nephrotoxicity; after adjustment, nephrotoxicity was not found to be an independent risk factor for mortality.
CMS is excreted primarily via renal route and its most important side effect is nephrotoxicity. Renal toxicity due to CMS is mainly manifested as acute tubular necrosis (7) . It has been shown to depend on the drug concentration and duration of treatment; a significant association has been found between cumulative doses and increased creatinine levels (21) (22) (23) . Additionally, the use of higher mean colistin doses per ideal body weight, simultaneous use of rifampin and co-administration of three or more nephrotoxic agents were reported as other nephrotoxicity risk factors (24) .
Rates of colistin related nephrotoxicity vary widely, ranging between 0-53.5%. Lower rates have been reported in more recent studies (8) . This is possibly due to the use of purified colistin, the use of CMS instead of colistin sulfate, more adequate dose adjustment according to renal function and improvements in treatment and follow-up (specifically the monitoring of hydration) of the ICU patients. Differences in the criteria used for evaluating nephrotoxicity may also explain part of the variance in the rates. RIFLE criteria are more sensitive to changes in renal function. As a result, nephrotoxicity rate has been reported to be higher in studies which used these criteria (25, 26) .
The rate of nephrotoxicity in this study was 62.3%, well above the previously reported range. This high rate could partly be explained with the use of RIFLE criteria; but when we analyzed the data to determine other contributory factors, the use of the domestic colistin brand with high dose, increased age, male gender, presence of hypertension, red blood cells replacement therapy, absence of acute kidney injury and low RIFLE stage were found to be associated with nephrotoxicity. The increased associated with low RIFLE stage is related to the methodology of RIFLE classification. The classification is done using the basal creatinine value, thus small increases in low baseline creatinine value more easily raise the RIFLE stage.
The association with between used drug brand and nephrotoxicity was unexpected, and patients using the two different brands were compared regarding exposure to other risk factors. The rates of concomitant use of nephrotoxic drugs were similar, and patients who received the imported CMS brand actually had worse risk factors, including higher rates of heart failure, sepsis and diuretic use. On the other hand, the domestic brand was administered at a significantly higher dose, as per the manufacturers' commendations, which is possibly the underlying reason for increased nephrotoxicity. This was an alarming finding and the authorities were immediately informed.
A smaller Turkish study evaluated the efficacy and safety of imported CMS in 24 patients with nosocomial infections caused by MDR gram-negative bacteria. CMS was administered at daily doses of 90-180 mg CBA. Nephrotoxicity developed in 7.7% and 18.2% of the patients treated with low and high doses, respectively. These difference from our results in nephrotoxicity rates may be explained with the differences in methods used to define nephrotoxicity (0.5 mg/dL increase in level of creatinine), and in patient populations (all cases had normal baseline renal function) (27 (29) . This factor was not seen as an important contributing factor to the high rate observed in our study. Balkan et al. have shown that colistin induced nephrotoxicity was more frequently seen in patients older than 60 years of age, with low initial glomerular filtration rate and high Charlson co-morbidity index (30) .
The overall mortality rate was high, as expected in a high-risk group with nosocomial pneumonia due to MDR bacteria. Similar rates have been reported in similar patient populations, whereas lower rates were observed in younger patients with less severe disease (9, 31) . Although the mortality rate was higher in our patients with nephrotoxicity, the only independent risk factors for mortality were older age, lack of response to treatment and presence of HAP-related septic shock. These findings are consistent with previous reports on mortality in patients with HAP and VAP (32, 33) .
This study has several limitations. First, the data were gathered from a retrospective review of patient charts and thus not all data were obtained from all patients.
On the other hand, we were able to collect the data for all parameters (except for the follow-up bacteriology results) from more than 90% of the patients and to reach a high number of patients from seven centers. Second, we could not calculate the cumulative doses of CMS, as the patients' discharge reports did not include daily changes in colistin doses. Besides, serum colistin levels were not monitored in any of the patients, as this analysis is not available in any of the participating centers. Different results might have been obtained, if cumulative doses or serum concentrations had been entered into the analysis. Third, although the use of all potentially nephrotoxic drugs used during the hospitalization period was recorded and analyzed, no reliable data could be obtained regarding the use of these drugs prior to hospital admission. Fourth, comparison of the nephrotoxicity rates in this and other studies is somewhat problematic. Different criteria have been used in evaluating renal function. Besides, even when RIFLE scoring is used, there is still a debate about the creatinine level which should be accepted as the baseline. In previous studies; the pre-ICU, ICU admission and previous hospital discharge creatinine levels have been used for baseline renal function (34, 35) .
In conclusion, this large, multicenter study showed that a considerable group of patients with HAP due to MDR gram-negative microorganisms could successfully be treated with CMS, but this was associated with unacceptably high rates of nephrotoxicity. The rate of nephrotoxicity was higher than previously reported and associated with older age, male gender, presence of hypertension, red blood cells transfusion, RIFLE stage and the use of colistin doses.
